Supernus Pharmaceuticals, Inc. (SUPN) revenue and earnings history
Supernus Pharmaceuticals, Inc. reported revenue of $719M for fiscal 2025 (year ended Dec 31, 2025), +8.6% on the year before, and net income of −$38.5M.
Over 15 years, from fiscal 2010 to fiscal 2025, revenue grew at a compound rate of +80.1% a year.
Revenue and net income, 16 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $719M+8.6% | −$62.3M | −$38.5M | $47.3M | $1.34M | $46M | $33.1M | — | — | $128M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Supernus Pharmaceuticals, Inc. (SUPN) on OQRO.
Common questions
What was Supernus Pharmaceuticals, Inc.'s revenue in fiscal 2025?
$719M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 2, 2026. That is +8.6% on fiscal 2024 ($662M).
How fast has Supernus Pharmaceuticals, Inc.'s revenue grown?
From $106K in fiscal 2010 to $719M in fiscal 2025: a compound annual growth rate of +80.1% over 15 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Supernus Pharmaceuticals, Inc. tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.